Dangaj lab

Our main goal is to understand tumor-intrinsic and extrinsic mechanisms that promote or dampen anti-tumor T cell immunity. To that end, my group explores the molecular states of tumor-infiltrating lymphocytes (TILs) and the tumor microenvironment (TME) at various stages of tumor rejection or escape, the mechanisms of TIL exclusion and dysfunction in the TME, the role of cancer cell genomic alterations and heterogeneity in regulating the inflammation status of TILs in tumors and the development of autologous 3D TME and systems immunology models to evaluate TIL reactivity for adoptive cell therapies. ...

Team

Denarda Dangaj

Group leader, Human integrated tumor immunology discovery engine (Hi-TIDe), Department of Oncology UNIL & CHUV, Ludwig Institute for Cancer Research Lausanne

denarda.dangaj@chuv.ch

Other members

David Barras

Bioinformatician, UNIL & CHUV

Charlotte Capt

Bioinformatician, UNIL & CHUV

Mathieu Desbuisson

Laboratory Technician, UNIL & CHUV

Noemie Fahr

Laboratory Technician, UNIL & CHUV

Alizee Grimm

Postdoctoral Fellow, UNIL & CHUV

Doga Gulhan

Visiting Fellow, Harvard Medical School, UNIL & CHUV

Maria Masid Barcon

Visiting Fellow, EPFL, UNIL & CHUV

Aspram Minasyan

Postdoctoral Fellow, UNIL & CHUV

Matteo Morotti

Postdoctoral Fellow, UNIL & CHUV

Tania Santoro

Laboratory Technician, UNIL & CHUV

Selected Publications

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.

Lanitis E, Kosti P, Ronet C, (...), Dangaj Laniti D, Coukos G, Irving M

Journal for immunotherapy of cancer – 2021 Aug 20

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.

Bruand M, Barras D, Mina M, (...), Martinon F, Dangaj Laniti D, Coukos G

Cell reports – 2021 Jul 20

Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.

Baumgaertner P, Sankar M, Herrera F, (...), Xenarios I, Guex N, Harari A

Frontiers in immunology – 2021 Apr 30

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.

Lanitis E, Rota G, Kosti P, (...), Dangaj D, Coukos G, Irving M

The Journal of experimental medicine – 2021 Feb 1

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.

Adams SF, Grimm AJ, Chiang CL, (...), Coukos G, Gimotty PA, Kandalaft LE

Journal for immunotherapy of cancer – 2020 Aug 20

Tumor Landscapes: β-Catenin Drives Immune Desertification.

Dangaj D, Barras D, Coukos G

Clinical cancer research : an official journal of the American Association for Cancer Research – 2019 Mar 5

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, (...), Harari A, Coukos G, Kandalaft LE

Science translational medicine – 2018 Apr 11

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, (...), Kandalaft LE, Coukos G, Harari A

Nature communications – 2018 Mar 15

Mechanisms regulating T-cell infiltration and activity in solid tumors.

Lanitis E, Dangaj D, Irving M, Coukos G

Annals of oncology : official journal of the European Society for Medical Oncology – 2017 Dec 1

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Smith JB, Lanitis E, Dangaj D, (...), Stashwick C, Scholler N, Powell DJ Jr

Molecular therapy : the journal of the American Society of Gene Therapy – 2016 Jul 21

Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

Zsiros E, Dangaj D, June CH, Kandalaft LE, Coukos G

Oncoimmunology – 2015 Oct 19

Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.

Dangaj D, Scholler N

Oncoimmunology – 2013 Jul 31

Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.

Lanitis E, Dangaj D, Hagemann IS, (...), Sandaltzopoulos R, Coukos G, Powell DJ Jr

PloS one – 2012 Nov 26